Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Japan Should Not Copy Foreign HTA Systems: Mr Grainger of PhRMA
July 12, 2012
- JMA Asks Sanofi Pasteur to Lower Price for Inactivated Polio Vaccine
July 9, 2012
- 60% of Respondents Are Unaware That Colorectal Cancer is Asymptomatic Ill: Survey
July 9, 2012
- OPIR Says Surplus of Drug Imports “Unrelated to International Competitiveness of Domestic Industry”
July 6, 2012
- JPMA Calls for Restoration of 30% Maximum Deduction Rate in R&D Tax Credit System
July 4, 2012
- 30% of Medical Institutions Introduce Generic Name Prescribing: Yakukeiren Survey
July 3, 2012
- JGA Begins Posting Information on Out-of-Stock Products, Delayed Shipments on Website
July 3, 2012
- JPA Vice President Miura Calls for Discussions on Role of Pharmacies; Raises Question about Dividends Paid by Listed Pharmacies
June 27, 2012
- Legal Prescription Receipt Rate at Record-High 64.6% in FY2011: JPA
June 26, 2012
- JPWA, NPhA Confirm Need for Thorough Efforts “at Ground Level” for Distribution Improvements
June 25, 2012
- Products from 2nd Round of Development Requests Now Eligible for PDSC Subsidies
June 19, 2012
- Astellas’ Nogimori New Acting President of IFPMA
June 18, 2012
- NPhA Survey: Nearly Half of Pharmacy Operators Have Received No Price Offers from Wholesalers
June 18, 2012
- Generic Market Share Increases Marginally to 23.3% in FY2011: JGA
June 18, 2012
- Drugs Developed in Response to Gov’t Request Should Be Exempted from Downward Foreign Average Price Adjustment: FPMAJ
June 13, 2012
- 48 Products Subjected to Market Expansion Re-Pricing in FY2012: FPMAJ Survey
June 13, 2012
- Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ
June 12, 2012
- FPMAJ’s Subcommittee Calls for Discussion on Need for “Ad Hoc Price Reduction” for Long-Listed Drugs
June 12, 2012
- FPMAJ’s NHI Drug Price Study Committee to Set Up Task Forces for Long-Listed Products, Cost Effectiveness
June 11, 2012
- Chairman Kamoya of FPMAJ’s Committee on NHI Drug Pricing Expresses Concern Over Long-Listed Drugs
June 11, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…